Skip to main content
Hannah Asghari, MD, Oncology, Lancaster, CA, City of Hope Comprehensive Cancer Center

HannahHamidehAsghariMD(She/Her)

Oncology Lancaster, CA

Hematologic Oncology

Hematologist/Oncologist

Dr. Asghari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Asghari's full profile

Already have an account?

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017 - 2020
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2014

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2017 - 2025
  • CA State Medical License
    CA State Medical License Active through 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
    Hannah H Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
    Hannah Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
    Hannah Asghari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Hospital Affiliations